White mulberry, Morus alba, the exact species named in this trial as the source of the alpha glucosidase inhibitor DNJ, one of the three ingredients tested
Forest and Kim StarrCC BY 3.0 US
Illustrative: the exact species named in the trial, not the manufactured extract or capsule form actually used in the study.
A 93 Person Trial Raised Insulin Sensitivity 28%, and Nobody Can Say Which Ingredient Did the Work
Berberine has been marketed as nature's Ozempic for a while now, and a new trial just gave that phrase its first real human data. The results are genuinely strong. They also come with a catch the study's own authors flag, and a live regulatory warning that almost nobody selling this combination is telling you about.
- A randomized controlled trial in 93 adults with obesity tested a combination of berberine, white mulberry leaf extract and chromium picolinate against placebo for 12 weeks, measuring insulin sensitivity with a real physiological test, not a self reported survey.
- The combination raised insulin sensitivity 28% and cut total body fat mass by 2.35 kilograms, alongside meaningful drops in BMI and visceral fat rating.
- The trial had no single ingredient arms, so its own authors say nobody can determine which of the three ingredients actually did the work, or whether they genuinely work better together.
- The European Food Safety Authority currently cannot establish a safe daily intake for berberine, citing data gaps and possible genotoxicity, a live safety question this trial does not resolve.
What a 12 week trial in 93 adults actually found
Researchers randomized 93 adults with obesity and no diagnosed chronic disease to either a combination supplement, berberine, white mulberry leaf extract and chromium picolinate, or a placebo, for 12 weeks. Insulin sensitivity was measured with the Matsuda index, calculated from a 75 gram oral glucose tolerance test, a real physiological measure rather than a questionnaire. Adjusted for baseline differences, the combination group saw insulin sensitivity rise 28% versus placebo, along with an adjusted BMI difference of negative 1.24 kilograms per meter squared, total body fat mass down 2.35 kilograms, and visceral fat rating down 0.92 units.
The three ingredients work through different mechanisms on paper. Berberine activates AMPK, the cell's energy balance switch. White mulberry leaf supplies 1-deoxynojirimycin, an alpha glucosidase inhibitor that slows carbohydrate digestion and blunts the post meal glucose spike, which in turn lowers insulin secretion and limits fat storage. Chromium is proposed to enhance insulin binding and increase active receptor numbers. Plausible as a combination. Unproven as one.
The catch the authors put in writing
Here is the part most coverage of this trial will skip. The study included no single ingredient arms, meaning nobody took berberine alone, mulberry leaf alone, or chromium alone for comparison. The authors state it directly: because no single agent arms were included, individual component contributions and synergy remain undetermined. If a brand tells you their berberine specifically is responsible for a result like this, that claim goes further than this trial, or any trial like it, currently supports. The visceral fat number carries its own asterisk too. It was measured by a bioimpedance style rating, not by an MRI or DXA scan, and the researchers themselves say imaging would be required before making any mechanistic claim about visceral fat specifically.
because no single agent arms were included, individual component contributions and synergy remain undetermined
Honest caveat
This is a single trial, 93 people, 12 weeks, in adults with obesity but no diagnosed chronic disease, and it has not been replicated. Effects in people with type 2 diabetes or PCOS, the populations most likely to actually be marketed this combination, were not tested here, and the authors themselves call for exactly those studies next. The trial included no single ingredient arms, so individual component contributions and any real synergy between berberine, mulberry leaf and chromium remain undetermined, a limitation the authors state directly rather than one this article is inferring. Visceral fat was measured by rating, not imaging, and the researchers say MRI or DXA would be needed before drawing a mechanistic conclusion about visceral fat specifically. Separately and importantly, the European Food Safety Authority currently cannot establish a safe daily intake for berberine, citing data gaps and possible genotoxicity, an unresolved and unfavorable regulatory position that this trial's results do not address or resolve. Funding and sponsor relationships were not stated in the available coverage of this trial, so treat commercial interest as unknown rather than absent. The study was published in Nutrients, a journal whose review rigor is contested in the field.
What this means for you
If you are already taking a berberine blend, the EFSA position is the single most important thing in this article, more important than the 28% number. A regulator being unable to establish a safe daily intake is not the same as a product being dangerous, but it is a real, current gap in the safety picture that deserves more attention than it is getting. If you are considering starting one because of headlines calling this nature's Ozempic, know that this trial never compared the combination against an actual GLP-1 drug, only against placebo, and that the real result, while genuinely meaningful, is not the same magnitude as what injectable GLP-1 medications produce. The honest summary is that this combination has its best human evidence yet, and its biggest open questions, arriving at the same time.
Primary sources
Common questions
Is this berberine blend as good as Ozempic?
No, and this trial does not test that comparison at all. It measured insulin sensitivity and body composition against a placebo, not against a GLP-1 drug, and the effect sizes here are meaningfully smaller than what injectable GLP-1 drugs produce. Nature's Ozempic is a marketing phrase, not a finding from this study.
Which ingredient in the blend actually worked, the berberine, the mulberry leaf, or the chromium?
Nobody knows, and the study's own authors say so directly. Because there were no single ingredient arms in the trial, individual component contributions and whether the three actually synergize remain undetermined. Any brand claiming a specific ingredient in this combination drove the result is going beyond what this data can show.
Is berberine safe to take?
The European Food Safety Authority currently cannot establish a safe daily intake for berberine, citing data gaps and possible genotoxicity concerns. That review is unresolved and unfavorable, which matters if you are already taking or considering a berberine supplement. This trial's own results do not resolve that separate safety question.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.